Buy Nectar Lifesciences; tgt of Rs 46: Firstcall Research

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Firstcall Research report on Nectar Lifesciences “Nectar Lifesciences Limited incorporated in 1995, an integrated pharmaceutical company, primarily manufactures various active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and Chiral resolution; and chemical and analytical development, and analytical and manufacturing services, as well as engineering consulting services. Its APIs and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime hcl, cephalothin, cefazolin sodium cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspension, and granules and injectibles. In addition, the company offers generic and OTC products for various therapeutic areas; a range of diagnostics products; empty hard gelatin capsules; and manufactures menthol and allied products, including menthol crystals, menthol flakes, peppermint oil, cis 3 hexenol, mentha piperita, Indian spearmint oil, menthones, mint blends, dementholised peppermint oil, and other customized mint based products.” “At the current market price of Rs. 37.15, the stock P/E ratio is at 11.93 x FY15E and 10.73 x FY16E respectively. Earnings per share (EPS) of the company for the earnings for FY15E and FY16E are seen at Rs. 3.12 and Rs. 3.46 respectively. Net Sales and Operating Profit of the company are expected to grow at a CAGR of 6% and 5% over 2013 to 2016E respectively. On the basis of EV/EBITDA, the stock trades at 5.03 x for FY15E and 4.68 x for FY16E. Price to Book Value of the stock is expected to be at 0.84 x and 0.78 x respectively for FY15E and FY16E. We recommend ‘BUY’ in this particular scrip with a target price of Rs. 46.00 for Medium to Long term Investment,” says Firstcall Research report.

For all recommendations, click here 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More